|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets: | ||||||||||||
| Current assets | ||||||||||||
| Cash balance | ||||||||||||
| Net trade accounts receivable | ||||||||||||
| Prepaid | ||||||||||||
| Marketable securities | ||||||||||||
| Original issuance discount, net | ||||||||||||
| Deferred financing costs, net | ||||||||||||
| Other assets | ||||||||||||
| Total current assets | ||||||||||||
| Original issuance discount | ||||||||||||
| Goodwill | ||||||||||||
| Capitalized computer software, net | ||||||||||||
| Capitalized website development costs, net | ||||||||||||
| Investment in private securities | ||||||||||||
| Furniture, fixtures, and equipment | ||||||||||||
| Total assets | ||||||||||||
| Liabilities and stockholders’ equity (deficit): | ||||||||||||
| Payroll liabilities related party | ||||||||||||
| Accounts payable | ||||||||||||
| Related Party | ||||||||||||
| Total accounts payable | ||||||||||||
| Accounts payable and accrued liabilities | ||||||||||||
| Accrued expenses | ||||||||||||
| Accrued expenses – related party | ||||||||||||
| Notes payable | ||||||||||||
| Convertible promissory notes | ||||||||||||
| Accrued interest | ||||||||||||
| Deferred revenue | ||||||||||||
| Total current liabilities | ||||||||||||
| PPP loan | ||||||||||||
| Notes payable - non-current | ||||||||||||
| Accrued interest-non-current | ||||||||||||
| Senior secured convertible promissory note, face value | ||||||||||||
| Less: Unamortized debt discount | ||||||||||||
| Convertible note payable, net of unamortized discount | ||||||||||||
| Derivative liability | ||||||||||||
| Total long-term liabilities | ||||||||||||
| Total liabilities | ||||||||||||
| Stockholders’ equity: | ||||||||||||
| Common stock, par value $0.0001, 300,000,000 shares authorized; 39,252,186 and 31,342,285 shares issued and outstanding, as of June 30, 2026 and December 31, 2025, respectively | ||||||||||||
| Deferred stock-based compensation | ||||||||||||
| Additional paid-in capital | ||||||||||||
| Accumulated deficit | ||||||||||||
| Total stockholders’ equity (deficit) | ||||||||||||
| Total liabilities and stockholders’ equity: |
Loading...